Pfizer Says Its COVID-19 Pill Paxlovid Fails to Prevent Symptomatic Infection of Household Members

Pfizer Says Its COVID-19 Pill Paxlovid Fails to Prevent Symptomatic Infection of Household Members
Paxlovid, a Pfizer's COVID-19 pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on Nov. 16, 2021. Pfizer/Handout via Reuters
Updated:

Pfizer announced Friday that a recent large, late-stage trial found that its COVID-19 antiviral pill, Paxlovid, failed at preventing symptomatic infection of people living with a person who has the disease.

The trial enrolled 2,957 participants aged 18 and older who live in the same household as another person who has COVID-19 with symptoms. They were given either Paxlovid or a placebo twice daily for five or 10 days.